HondurasTuberculosis profile
Population  2016 9.1 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.37 (0.21–0.58) 4.1 (2.3–6.4)
Mortality (HIV+TB only) 0.066 (0.047–0.087) 0.72 (0.52–0.95)
Incidence  (includes HIV+TB) 3.6 (2.8–4.6) 40 (30–50)
Incidence (HIV+TB only) 0.31 (0.24–0.4) 3.4 (2.6–4.3)
Incidence (MDR/RR-TB)** 0.12 (0.059–0.17) 1.3 (0.65–1.9)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.22 (0.16–0.27) 1.3 (0.96–1.6) 1.5 (1.1–1.9)
Males 0.25 (0.18–0.31) 1.9 (1.4–2.3) 2.1 (1.6–2.6)
Total 0.46 (0.35–0.58) 3.1 (2.4–3.9) 3.6 (2.8–4.6)
TB case notifications, 2016  
Total cases notified 2 886
Total new and relapse 2 886
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 88%
          - % pulmonary 88%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.12 (0.07–0.19)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 207 8%
          - on antiretroviral therapy 175 85%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  93
(51–140)
Estimated % of TB cases with MDR/RR-TB 2.2% (0.69–3.7) 21% (9.2–32)  
% notified tested for rifampicin resistance 7% 47% 292
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 20, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 20, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 86% 2 906
Previously treated cases, excluding relapse, registered in 2015 54% 13
HIV-positive TB cases registered in 2015 67% 267
MDR/RR-TB cases started on second-line treatment in 2014 38% 8
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 42%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions) 11
Funding source: 17% domestic, 31% international, 52% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-05-24 Data: www.who.int/tb/data